岭南现代临床外科2024，Vol.24Issue(5)：284-290,7.DOI:10.3969/j.issn.1009-976X.2024.05.003
HAIC联合仑伐替尼和PD-1抗体对比HAIC联合仑伐替尼转化治疗肝细胞癌的回顾性研究
A retrospective study of HAIC in combination with lenvatinib and PD-1 antibody versus HAIC in combination with lenvatinib for the translational treatment of hepatocellular carcinoma
摘要
Abstract
Objective To retrospectively analyze the efficacy and prognosis of HAIC combined with lenvatinib and PD-1 antibody in the treatment of hepatocellular carcinoma in patients with intermediate and advanced hepatocellular carcinoma in our center.Methods Sixty-five patients admitted to Zhong-shan People's Hospital from March 2020 to March 2023 were retrospectively collected and divided into a combination group(HAIC combined with lenvatinib and PD-1 antibody)and a control group(HAIC combined with lenvatinib)according to the different treatment regimens,and the overall survival(OS),disease progression-free survival(PFS),and treatment-related adverse effects of the patients in the two groups were statistically analyzed.Results Sixty-five patients with hepatocellular carcinoma were evaluated for treatment according to RECIST 1.1 and mRECIST criteria,respectively,According to the mRECIST criteria,there were 29 cases(74.4%)of PR,35 cases(89.7%)of ORR,and 37 cases(94.9%)of DCR in the combined group;In the control group,there were 9 cases of PR(74.4%),17 cases of ORR(65.4%),and 24 cases of DCR(92.3%);the overall median survival time was about 36 months,and the overall median relapse-free survival was about 28 months.The median survival time for patients in the combination group was 40 months,and the median relapse-free survival was 32 months.Patients in the control group had a median survival time of 29 months and a median relapse-free survival of 25 months.The PR,ORR,OS and RFS of the combination group were significantly higher than those of the control group,which were statistically different.Conclusion HAIC combined with lenvatinib and PD-1 antibody can bring more significant survival advantages for patients with intermediate and advanced HCC,effectively prolonging the survival of intermediate and advanced patients and improving the quality of patients' survival.关键词
肝细胞癌/肝动脉灌注化疗/FOLFOX方案/联合治疗Key words
hepatocellular carcinoma/hepatic artery perfusion chemotherapy/FOLFOX regimen/combination therapy分类
医药卫生引用本文复制引用
黄东东,田丰,方郁晖,邱益霖,何坤..HAIC联合仑伐替尼和PD-1抗体对比HAIC联合仑伐替尼转化治疗肝细胞癌的回顾性研究[J].岭南现代临床外科,2024,24(5):284-290,7.基金项目
中山市医学科研项目(20211A020295) （20211A020295）
